Introduction
coronavirus disease 2019
CORONAVIRUS, CRITICAL ILLNESS, SEVERE ACUTE RESPIRATORY SYNDROME, CORONAVIRUS DISEASE 2019
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the culprit of coronavirus disease 2019 (COVID-19), is continuously evolving globally [Several therapeutic approaches have been developed to reduce the symptom burden and the probability of progression into severe or critical illness. These mainly include antivirals (e.g. nirmatrelvir-ritonavir, monulpiravir, VV116) [Several traditional Chinese medicine formulae have been marketed and endorsed for clinical application by the We conducted the randomized, double-blind, international, multicenter, investigator-initiated clinical trial to investigate the efficacy and safety of Lianhuaqingwen capsules compared to placebo and combined with standard-of-care in adult patients with mild-to-moderate COVID-19 (FLOSAN study). We hypothesized that LHQW capsules would accelerate symptom recovery among adults with mild-to-moderate COVID-19.